The cytotoxicity of gefitinib on patient‑derived induced pluripotent stem cells reflects gefitinib‑induced liver injury in the clinical setting

Gefitinib is a key drug used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Gefitinib therapy is superior to conventional chemotherapy for the progression-free survival rate of patients with EGFR mutations. However, 10–26% of patients develop grade 3 or higher hepatotoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisaka, Yasuhito, Nakagawa, Takatoshi, Tomoda, Kiichiro, Watanabe, Marina, Matsunaga, Ninso, Tamura, Yosuke, Ikeda, Soichiro, Imagawa, Akihisa, Asahi, Michio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623090/
https://www.ncbi.nlm.nih.gov/pubmed/37927418
http://dx.doi.org/10.3892/ol.2023.14108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623090/
https://www.ncbi.nlm.nih.gov/pubmed/37927418
http://dx.doi.org/10.3892/ol.2023.14108

Ejemplares similares